nach oben

Breast Cancer Research and Treatment

Erschienen in:

01.12.2012 | Epidemiology

Three novel functional polymorphisms in the promoter of FGFR2 gene and breast cancer risk: a HuGE review and meta-analysis

verfasst von: Liping Zhou, Fan Yao, Hong Luan, Yinling Wang, Xihua Dong, Wenwen Zhou, Qihui Wang

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Published data on the association between three novel functional polymorphisms (rs11200014, rs2981579, and rs2981578) in the promoter of FGFR2 gene and breast cancer risk are inconclusive. The aim of this human genome epidemiology review and meta-analysis was to derive a more precise estimation of the relationship. A literature search of Pubmed, Embase, Web of science, and CBM databases from inception through July 2012 was conducted. Seventeen studies were included with a total of 21,742 breast cancer cases and 31,125 healthy controls. Crude odds ratios (ORs) with 95 % confidence intervals (CIs) were used to assess the strength of association in allele model, dominant model, recessive model, homozygous model, and heterozygous model. When all the eligible studies were pooled into the meta-analysis, remarkable associations between the rs11200014 (A>G) polymorphism and breast cancer risk were detected in Caucasians (G vs. A: OR = 1.28, 95 % CI: 1.21–1.35; GG/AG vs. AA: OR = 1.32, 95 % CI: 1.18–1.48), but not in Asians and Africans. In addition, there were statistically significant associations between the rs2981579 (G>A) polymorphism and increased risk of breast cancer risk in all ethnicities (A vs. G: OR = 1.20, 95 % CI: 1.11–1.29; AA/GA vs. GG: OR = 1.32, 95 % CI: 1.18–1.48; AA vs. GG: OR = 1.67, 95 % CI: 1.55–1.81), including Caucasians, Asians, and Africans. However, the TT genotype of rs2981578 (C>T) polymorphism might decrease breast cancer risk (TT vs. CC/CT: OR = 0.55, 95 % CI: 0.38–0.79; TT vs. CC: OR = 0.51, 95 % CI: 0.35–0.76; TT vs. CT: OR = 0.58, 95 % CI: 0.40–0.85), especially among Asians. Results from the current meta-analysis indicates that three novel functional polymorphisms (rs11200014, rs2981579, and rs2981578) in the promoter of FGFR2 gene are associated with breast cancer susceptibility and might be a potential biomarkers for breast cancer risk.

Shulman LN, Willett W, Sievers A, Knaul FM (2010) Breast cancer in developing countries: opportunities for improved survival. J Oncol 2010:595167. doi:10.1155/2010/595167 PubMedCrossRef

Coughlin SS, Ekwueme DU (2009) Breast cancer as a global health concern. Cancer Epidemiol 33:315–318. doi:10.1016/j.canep.2009.10.003 PubMedCrossRef

Benson JR, Jatoi I (2012) The global breast cancer burden. Future Oncol 8:697–702. doi:10.2217/fon.12.61 PubMedCrossRef

Abdulrahman GOJ, Rahman GA (2012) Epidemiology of breast cancer in Europe and Africa. J Cancer Epidemiol 2012:915610. doi:10.1155/2012/915610 PubMed

Nelson HD, Walker M, Zakher B, Mitchell J (2012) Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Preventive Services task force recommendations. Ann Intern Med 157:104–113. doi:10.7326/0003-4819-157-2-201207170-00466 PubMed

Saether S, Bakken K, Lund E (2012) The risk of breast cancer linked to menopausal hormone therapy. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 132:1330–1334. doi:10.4045/tidsskr.11.1055 CrossRef

Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, Cox A, Fasching PA, Hein R, Spurdle AB, Blows F, Driver K, Flesch-Janys D, Heinz J, Sinn P, Vrieling A, Heikkinen T, Aittomaki K, Heikkila P, Blomqvist C, Lissowska J, Peplonska B, Chanock S, Figueroa J, Brinton L, Hall P, Czene K, Humphreys K, Darabi H, Liu J, Van’t Veer LJ, van Leeuwen FE, Andrulis IL, Glendon G, Knight JA, Mulligan AM, O’Malley FP, Weerasooriya N, John EM, Beckmann MW, Hartmann A, Weihbrecht SB, Wachter DL, Jud SM, Loehberg CR, Baglietto L, English DR, Giles GG, McLean CA, Severi G, Lambrechts D, Vandorpe T, Weltens C, Paridaens R, Smeets A, Neven P, Wildiers H, Wang X, Olson JE, Cafourek V, Fredericksen Z, Kosel M, Vachon C, Cramp HE, Connley D, Cross SS, Balasubramanian SP, Reed MW, Dork T, Bremer M, Meyer A, Karstens JH, Ay A, Park-Simon TW, Hillemanns P, Arias Perez JI, Menendez Rodriguez P, Zamora P, Benitez J, Ko YD, Fischer HP, Hamann U, Pesch B, Bruning T, Justenhoven C, Brauch H, Eccles DM, Tapper WJ, Gerty SM, Sawyer EJ, Tomlinson IP, Jones A, Kerin M, Miller N, McInerney N, Anton-Culver H, Ziogas A et al (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 103:250–263. doi:10.1093/jnci/djq526 PubMedCrossRef

Stoppa-Lyonnet D, Buecher B, Houdayer C, de Pauw A, Gauthier-Villars M, de la Rochefordiere A, This P, Asselain B, Andrieu N (2009) Implications of genetic risk factors in breast cancer: culprit genes and associated malignancies. Bull Acad Natl Med 193:2063–2083 Discussion 2084–2065PubMed

Fu F, Wang C, Huang M, Song C, Lin S, Huang H (2012) Polymorphisms in second intron of the FGFR2 gene are associated with the risk of early-onset breast cancer in Chinese Han women. Tohoku J Exp Med 226:221–229PubMedCrossRef

10.

Tenhagen M, van Diest PJ, Ivanova IA, van der Wall E, van der Groep P (2012) Fibroblast growth factor receptors in breast cancer: expression, downstream effects, and possible drug targets. Endocr Relat Cancer 19:R115–R129. doi:10.1530/ERC-12-0060 PubMedCrossRef

11.

Meyers GA, Day D, Goldberg R, Daentl DL, Przylepa KA, Abrams LJ, Graham JM Jr, Feingold M, Moeschler JB, Rawnsley E, Scott AF, Jabs EW (1996) FGFR2 exon IIIa and IIIc mutations in Crouzon, Jackson-Weiss, and Pfeiffer syndromes: evidence for missense changes, insertions, and a deletion due to alternative RNA splicing. Am J Hum Genet 58:491–498PubMed

12.

Katoh M (2008) Cancer genomics and genetics of FGFR2 (Review). Int J Oncol 33:233–237PubMed

13.

Gartside MG, Chen H, Ibrahimi OA, Byron SA, Curtis AV, Wellens CL, Bengston A, Yudt LM, Eliseenkova AV, Ma J, Curtin JA, Hyder P, Harper UL, Riedesel E, Mann GJ, Trent JM, Bastian BC, Meltzer PS, Mohammadi M, Pollock PM (2009) Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol Cancer Res 7:41–54. doi:10.1158/1541-7786.MCR-08-0021 PubMedCrossRef

14.

Grose R, Dickson C (2005) Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 16:179–186. doi:10.1016/j.cytogfr.2005.01.003 PubMedCrossRef

15.

Moffa AB, Ethier SP (2007) Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells. J Cell Physiol 210:720–731. doi:10.1002/jcp.20880 PubMedCrossRef

16.

Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, Chatterjee N, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Hayes RB, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover RN, Thomas G, Chanock SJ (2007) A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 39:870–874. doi:10.1038/ng2075 PubMedCrossRef

17.

Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, Healey CS, Bowman R, Meyer KB, Haiman CA, Kolonel LK, Henderson BE, Le Marchand L, Brennan P, Sangrajrang S, Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC, Eccles D, Evans DG, Peto J, Fletcher O, Johnson N, Seal S, Stratton MR, Rahman N, Chenevix-Trench G, Bojesen SE, Nordestgaard BG, Axelsson CK, Garcia-Closas M, Brinton L, Chanock S, Lissowska J, Peplonska B, Nevanlinna H, Fagerholm R, Eerola H, Kang D, Yoo KY, Noh DY, Ahn SH, Hunter DJ, Hankinson SE, Cox DG, Hall P, Wedren S, Liu J, Low YL, Bogdanova N, Schurmann P, Dork T, Tollenaar RA, Jacobi CE, Devilee P, Klijn JG, Sigurdson AJ, Doody MM, Alexander BH, Zhang J, Cox A, Brock IW, MacPherson G, Reed MW, Couch FJ, Goode EL, Olson JE, Meijers-Heijboer H, van den Ouweland A, Uitterlinden A, Rivadeneira F, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Hopper JL, McCredie M, Southey M, Giles GG, Schroen C, Justenhoven C, Brauch H, Hamann U, Ko YD, Spurdle AB, Beesley J, Chen X, Mannermaa A, Kosma VM, Kataja V, Hartikainen J, Day NE et al (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447:1087–1093. doi:10.1038/nature05887 PubMedCrossRef

18.

Peng S, Lu B, Ruan W, Zhu Y, Sheng H, Lai M (2011) Genetic polymorphisms and breast cancer risk: evidence from meta-analyses, pooled analyses, and genome-wide association studies. Breast Cancer Res Treat 127:309–324. doi:10.1007/s10549-011-1459-5 PubMedCrossRef

19.

Jia C, Cai Y, Ma Y, Fu D (2010) Quantitative assessment of the effect of FGFR2 gene polymorphism on the risk of breast cancer. Breast Cancer Res Treat 124:521–528. doi:10.1007/s10549-010-0872-5 PubMedCrossRef

20.

Zhang J, Qiu LX, Wang ZH, Leaw SJ, Wang BY, Wang JL, Cao ZG, Gao JL, Hu XC (2010) Current evidence on the relationship between three polymorphisms in the FGFR2 gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 124:419–424. doi:10.1007/s10549-010-0846-7 PubMedCrossRef

21.

da Costa BR, Cevallos M, Altman DG, Rutjes AW, Egger M (2011) Uses and misuses of the STROBE statement: bibliographic study. BMJ Open 1:e000048. doi:10.1136/bmjopen-2010-000048 PubMedCrossRef

22.

Zhang L, Liu JL, Zhang YJ, Wang H (2011) Association between HLA-B*27 polymorphisms and ankylosing spondylitis in Han populations: a meta-analysis. Clin Exp Rheumatol 29:285–292PubMed

23.

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558. doi:10.1002/sim.1186 PubMedCrossRef

24.

Zintzaras E, Ioannidis JP (2005) Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 28:123–137. doi:10.1002/gepi.20048 PubMedCrossRef

25.

Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L (2006) Comparison of two methods to detect publication bias in meta-analysis. JAMA 295:676–680. doi:10.1001/jama.295.6.676 PubMedCrossRef

26.

Raskin L, Pinchev M, Arad C, Lejbkowicz F, Tamir A, Rennert HS, Rennert G, Gruber SB (2008) FGFR2 is a breast cancer susceptibility gene in Jewish and Arab Israeli populations. Cancer Epidemiol Biomarkers Prev 17:1060–1065. doi:10.1158/1055-9965.epi-08-0018 PubMedCrossRef

27.

Kawase T, Matsuo K, Suzuki T, Hiraki A, Watanabe M, Iwata H, Tanaka H, Tajima K (2009) FGFR2 intronic polymorphisms interact with reproductive risk factors of breast cancer: results of a case control study in Japan. Int J Cancer 125:1946–1952. doi:10.1002/ijc.24505 PubMedCrossRef

28.

Liu M, San KR, He Y, Zhang T, Qi XL, Zhao Y, Wu CX, Wang CJ, Wang XL, Guan ZZ, Ren XL (2009) The relationship between two FGFR2 polymorphisms and breast cancer. Chin J Clin Oncol 36:413–416. doi:10.3969/j.issn.1000-8179.2009.07.014

29.

Prentice RL, Huang Y, Hinds DA, Peters U, Pettinger M, Cox DR, Beilharz E, Chlebowski RT, Rossouw JE, Caan B, Ballinger DG (2009) Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer. Cancer Epidemiol Biomarkers Prev 18:3079–3085. doi:10.1158/1055-9965.epi-09-0611 PubMedCrossRef

30.

Thomas G, Jacobs KB, Kraft P, Yeager M, Wacholder S, Cox DG, Hankinson SE, Hutchinson A, Wang Z, Yu K, Chatterjee N, Garcia-Closas M, Gonzalez-Bosquet J, Prokunina-Olsson L, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Diver R, Prentice R, Jackson R, Kooperberg C, Chlebowski R, Lissowska J, Peplonska B, Brinton LA, Sigurdson A, Doody M, Bhatti P, Alexander BH, Buring J, Lee IM, Vatten LJ, Hveem K, Kumle M, Hayes RB, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover RN, Chanock SJ, Hunter DJ (2009) A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet 41:579–584. doi:10.1038/ng.353 PubMedCrossRef

31.

Udler MS, Meyer KB, Pooley KA, Karlins E, Struewing JP, Zhang J, Doody DR, MacArthur S, Tyrer J, Pharoah PD, Luben R, Bernstein L, Kolonel LN, Henderson BE, Le Marchand L, Ursin G, Press MF, Brennan P, Sangrajrang S, Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC, Kang D, Yoo KY, Noh DY, Ahn SH, Ponder BA, Haiman CA, Malone KE, Dunning AM, Ostrander EA, Easton DF (2009) FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Hum Mol Genet 18:1692–1703. doi:10.1093/hmg/ddp078 PubMedCrossRef

32.

Zheng W, Cai Q, Signorello LB, Long J, Hargreaves MK, Deming SL, Li G, Li C, Cui Y, Blot WJ (2009) Evaluation of 11 breast cancer susceptibility loci in African-American women. Cancer Epidemiol Biomarkers Prev 18:2761–2764. doi:10.1158/1055-9965.epi-09-0624 PubMedCrossRef

33.

Barnholtz-Sloan JS, Shetty PB, Guan X, Nyante SJ, Luo J, Brennan DJ, Millikan RC (2010) FGFR2 and other loci identified in genome-wide association studies are associated with breast cancer in African–American and younger women. Carcinogenesis 31:1417–1423. doi:10.1093/carcin/bgq128 PubMedCrossRef

34.

Zhou XK, Hua D, Guo ZJ, Huang ZH, Liu ZH, Song MX, Li LH (2010) Implication of the FGFR2 rs2981579 polymorphisms in breast cancer in Chinese Han women. Suzhou Univ J Med Sci 30:528–531

35.

Hu XP, Cui HY (2011) Association of FGFR2 polymorphisms with the risk of breast cancer in Chinese women of Ningxia Han population. Thesis for Master Degree at Ningxia Medical University

36.

Li X, Li M (2011) The breast cancer susceptive locus screening in Han Chinese women and meta-analysis on common breast cancer risk factors. Thesis for Master Degree at Southern Medical University

37.

Ma JM, Cao MZ, Ge YL, Ma ZL, Liu XY (2011) Relative research of FGFR2 gene single nucleotide polymorphism and breast neoplasm. Chinese Journal of Current Advances in General Surgery 14:111–115. doi:CNKI:SUN:PWJZ.0.2011-02-009

38.

Chen F, Lv M, Xue Y, Zhou J, Hu F, Chen X, Zhao Z, Li Y, Wang X (2012) Genetic variants of fibroblast growth factor receptor 2 (FGFR2) are associated with breast cancer risk in Chinese women of the Han nationality. Immunogenetics 64:71–76. doi:10.1007/s00251-011-0564-2 PubMedCrossRef

39.

Huo D, Zheng Y, Ogundiran TO, Adebamowo C, Nathanson KL, Domchek SM, Rebbeck TR, Simon MS, John EM, Hennis A, Nemesure B, Wu SY, Leske MC, Ambs S, Niu Q, Zhang J, Cox NJ, Olopade OI (2012) Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis 33:835–840. doi:10.1093/carcin/bgs093 PubMedCrossRef

40.

Lin CY, Ho CM, Bau DT, Yang SF, Liu SH, Lin PH, Lin TH, Tien N, Shih MC, Lu JJ (2012) Evaluation of breast cancer susceptibility loci on 2q35, 3p24, 17q23 and FGFR2 genes in Taiwanese women with breast cancer. Anticancer Res 32:475–482PubMed

41.

Zhao JD, Shen GS, Geng PL, Wang LJ, Cao CZ, He JX, Ji FX, Li JZ, Li GY (2012) Association of FGFR2 rs2981578 polymorphism with the risk of breast cancer in Chinese women of Qinhai Han and Zang populations. Chin J Clin Lab Sci 30:43–44

42.

Hutter CM, Young AM, Ochs-Balcom HM, Carty CL, Wang T, Chen CT, Rohan TE, Kooperberg C, Peters U (2011) Replication of breast cancer GWAS susceptibility loci in the Women’s Health Initiative African American SHARe Study. Cancer Epidemiol Biomarkers Prev 20:1950–1959. doi:10.1158/1055-9965.epi-11-0524 PubMedCrossRef

43.

Koziczak M, Holbro T, Hynes NE (2004) Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 23:3501–3508. doi:10.1038/sj.onc.1207331 PubMedCrossRef

44.

Tannheimer SL, Rehemtulla A, Ethier SP (2000) Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE. Breast Cancer Res 2:311–320PubMedCrossRef

45.

Ingersoll RG, Paznekas WA, Tran AK, Scott AF, Jiang G, Jabs EW (2001) Fibroblast growth factor receptor 2 (FGFR2): genomic sequence and variations. Cytogenet Cell Genet 94:121–126PubMedCrossRef

46.

Yang ZQ, Moffa AB, Haddad R, Streicher KL, Ethier SP (2007) Transforming properties of TC-1 in human breast cancer: interaction with FGFR2 and beta-catenin signaling pathways. Int J Cancer 121:1265–1273. doi:10.1002/ijc.22831 PubMedCrossRef

47.

Liang J, Chen P, Hu Z, Zhou X, Chen L, Li M, Wang Y, Tang J, Wang H, Shen H (2008) Genetic variants in fibroblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women. Carcinogenesis 29:2341–2346. doi:10.1093/carcin/bgn235 PubMedCrossRef

Titel: Three novel functional polymorphisms in the promoter of FGFR2 gene and breast cancer risk: a HuGE review and meta-analysis
verfasst von: Liping Zhou
Fan Yao
Hong Luan
Yinling Wang
Xihua Dong
Wenwen Zhou
Qihui Wang
Publikationsdatum: 01.12.2012
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-012-2300-5

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Three novel functional polymorphisms in the promoter of FGFR2 gene and breast cancer risk: a HuGE review and meta-analysis

Abstract

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells

Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast/ovarian cancer patients

The clinical consequences of hemizygosity across 2 MB of 10q23 are restricted to Cowden syndrome

Acknowledgement of reviewers 2011

The SLC4A7 variant rs4973768 is associated with breast cancer risk: evidence from a case–control study and a meta-analysis

Phase II open-label study of sunitinib in patients with advanced breast cancer

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie